Why is Island Pharmaceuticals stock rallying today?
- Investing.com
Metrics to compare | ILA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipILAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −12.9x | −6.8x | −0.4x | |
PEG Ratio | 0.21 | −0.09 | 0.00 | |
Price/Book | 9.5x | 2.7x | 2.6x | |
Price / LTM Sales | 450.2x | 6.7x | 3.0x | |
Upside (Analyst Target) | 272.1% | 198.2% | 54.5% | |
Fair Value Upside | Unlock | 21.9% | 7.2% | Unlock |
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.